FARAPULSE and WATCHMAN supporting comprehensive AF management through rhythm control and stroke prevention.

Treat Earlier. Protect for a Lifetime.

Supporting AF patients through timely rhythm control and lifelong stroke protection.

Comprehensive AF Management

Managing AF requires both rhythm control and stroke protection.

Although rhythm control is an important treatment goal, underlying stroke risk may still remain. Stroke protection should therefore be a lifelong consideration in patients with AF.

Patients with AF require lifelong management as symptoms, disease progression, and stroke risk evolve over time.

Boy and grandmother running together, representing quality of life after comprehensive AF management.

Treat Earlier

Early referral for rhythm-control evaluation matters

Catheter ablation has a Class IA recommendation by ESC1 as a first-line treatment option for selected categories of AF patients.

Early intervention may:

  • Improve symptoms1
  • Reduce AF burden
  • Improve quality of life
  • Slow disease progression

Learn about Catheter Ablation

FARAPULSE pulsed field ablation platform supporting rhythm control in patients with AF.

Protect for a Lifetime

Stroke protection is a constant consideration in AF patient management

For certain AF patients, Left Atrial Appendage Closure (LAAC) may be a pragmatic alternative for stroke protection.

There is a growing body of evidence to support referrals' decision making for the therapy of patients who are not suitable for long term oral anticoagulation
Learn about Stroke Protection

WATCHMAN left atrial appendage closure device supporting stroke prevention in patients with AF.

Comprehensive AF Care Starts with the Right Referral

From rhythm control to stroke protection, patients benefit from access to the full spectrum of evidence-based AF management options.


Refernces:
1. Isabelle C Van Gelder et al. ESC Scientific Document Group , 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO), European Heart Journal, Volume 45, Issue 36, 21 September 2024, Pages 3314–3414, https://doi.org/10.1093/eurheartj/ehae176

CAUTION:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.